Stockreport

Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting

UROVANT SCIENCES LTD COMMON  (UROV) 
Last urovant sciences ltd common earnings: 2/13 04:15 pm Check Earnings Report
PDF Second abstract with data concluding vibegron does not inhibit CYP2D6, a common drug metabolism pathway, also accepted for podium presentation [Read more]